María del Rosario
Vidal Tocino
Hospital General Universitario Gregorio Marañón
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (10)
2024
-
Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers
British Journal of Surgery, Vol. 111, Núm. 3
2023
-
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089
-
Telomere Length as a New Risk Marker of Early-Onset Colorectal Cancer
International Journal of Molecular Sciences, Vol. 24, Núm. 4
-
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology, Vol. 15
2022
2021
-
Cohort profile: The Spanish Early-onset Colorectal Cancer (SECOC) cohort: A multicentre cohort study on the molecular basis of colorectal cancer among young individuals in Spain
BMJ Open, Vol. 11, Núm. 12
-
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
Therapeutic Advances in Medical Oncology, Vol. 13
-
External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?
Gastric Cancer, Vol. 24, Núm. 2, pp. 445-456
-
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry
Gastric Cancer, Vol. 24, Núm. 4, pp. 926-936
2020
-
Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
PloS one, Vol. 15, Núm. 7, pp. e0235848